secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0000950170-24-003512
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint doses first patient in Phase 2 VERONA trial of EYP-1901 for DME
------------------------------------------------------------------------

- EYP-1901 (vorolanib/Durasert E) enters Phase 2 for diabetic macular edema; ~25 patients to be enrolled.
- Primary endpoint: time to first supplemental aflibercept injection up to 24 weeks.
- Topline data from VERONA expected in Q1 2025; PAVIA NPDR data due Q2 2024.
- First Phase 3 pivotal trial in wet AMD anticipated to start in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024003512/0000950170-24-003512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024003512/eypt-20240110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-003512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer